

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of Use of a PTH receptor agonist for ameliorating symptoms associated with the growth of bone metastasized cancer or bone-originated cancer, comprising administering to an individual in need thereof in the preparation of a medicament which, when administered to an individual in comprising an amount of PTH receptor agonist an effective amount reduces to reduce bone loss, reduces reduce bone fracturing, and/or reduces reduce pain.
2. (Currently Amended) Use The method according to claim 1, wherein said administered amount is effective amount reduces to reduce pain.
3. (Currently Amended) Use The method according to any of claims 1-2 claim 1, wherein said PTH receptor agonist is PTH or an analogue thereof.
4. (Currently Amended) Use The method according to claim 3, wherein said PTH or an analogue thereof is PTH (1-34), preferably teriparatide acetate.
5. (Currently Amended) Use The method according to any of claims 1-2 claim 1, wherein said PTH receptor agonist is parathyroid hormone-related protein or an analogue thereof.
6. (Currently Amended) Use The method according to any of claims 1-2 claim 1, wherein said individual has bone metastasized cancer.
7. (Currently Amended) Use The method according to claim 6, wherein said bone metastasized cancer is breast cancer, prostate cancer, lung cancer, kidney cancer or thyroid cancer or myeloma.
8. (Currently Amended) Use The method according to any of claims 1-2 claim 1, wherein said individual has bone-originated cancer.
9. (Currently Amended) Use The method according to any of claims 1-2 claim 1, wherein said bone originated cancer is sarcoma.
10. (Currently Amended) Use The method according to any one of claims 1-9 claim 1, wherein the effective amount of the PTH receptor agonist is from 0.1 to 1000 micrograms, preferably from 20 to 200 micrograms.

11. (New) The method according to claim 10, wherein the amount of the PTH receptor agonist is from 20 to 200 micrograms.
12. (New) The method according to claim 3, wherein said PTH or an analogue thereof is teriparatide acetate.
13. (New) A medicament for ameliorating symptoms associated with the growth of bone metastasized cancer or bone-originated cancer, comprising an amount of a PTH receptor agonist effective to reduce bone loss, reduce bone fracturing, and/or reduce pain in an individual in need thereof.
14. (New) The medicament according to claim 13, wherein said amount is effective to reduce pain.
15. (New) The medicament according to claim 13, wherein said PTH receptor agonist is PTH or an analogue thereof.
16. (New) The medicament according to claim 15, wherein said PTH or an analogue thereof is PTH(1-34).
17. (New) The medicament according to claim 15, wherein said PTH or an analogue thereof is teriparatide acetate.
18. (New) The medicament according to claim 13, wherein said PTH receptor agonist is parathyroid hormone-related protein or an analogue thereof.
19. (New) The medicament according to claim 13, comprising from 0.1 to 1000 micrograms of the PTH receptor agonist.
20. (New) The medicament according to claim 13, comprising from 20 to 200 micrograms of the PTH receptor agonist.